HUM-MOLGEN events: CHI's INTELLIGENT DRUG DISCOVERY & DEVELOPMENT 2002

HUM-MOLGEN -> Events -> Meetings and Conferences

CHI's INTELLIGENT DRUG DISCOVERY & DEVELOPMENT 2002

December 03, 2001

Cambridge Healthtech Institute, Philadelphia, Pennsylvania
2002-05-02

CHI's INTELLIGENT DRUG DISCOVERY & DEVELOPMENT 2002

Cambridge Healthtech Institute's Sixth Annual
Cheminformatics

Dr. Frank Brown introduced the term Chemoinformatics several years ago and defined it as 'the mixing of those information resources to transform data into information and information into knowledge for the intended purpose of making better decisions faster in the arena of drug lead identification and optimization'.

There are many sources of chemical data; registered chemical structures with stereochemistry, synthesis records, spectral data including NMR, purity determinations, not to mention the volume of data generated by HTS, SAR studies and the calculation of physiochemical properties. While gathering, storage and registration of data transforms it to information, it is accessibility, manipulation, and data mining of chemical information that translates it to knowledge for smarter drug development.

This conference will showcase chemoinformatic tools for storage, design and mining of chemical databases/information and present case examples of its success in lead identification and optimization.

Chemoinformatics is about presenting and integrating a vast and complex array of information so that people who make the decisions in drug discovery can make the correct choices quickly and easily. Anyone interested in gaining a competitive edge in drug discovery should consider attending.

Cambridge Healthtech Institute's Ninth Annual
High Throughput Screening and Technologies

For any given target, HTS remains the predominant tool for identifying leads for further drug development. Those companies that can effectively deal with the flood of large numbers of potential targets coming out of genomics are those that can gain a significant competitive advantage. However, this abundance of new targets is both an opportunity and a threat.

When companies are able to prioritize and validate targets, it allows them to narrow the focus to those leads offering improved chances of success. Those unable to keep up in this new "parallel" world will be left behind in the quagmire of huge expenditures in time and money. The inability to effectively validate and prioritize this large number of potential targets-many more than just a few years ago-means the risk of failure is even higher than failure rates of the past. This conference will explore the new techniques and technologies for speeding the drug discovery process and providing the best possible leads to continue through the pipeline.

Researchers in these areas are encouraged to submit a one-page abstract for consideration for oral or poster presentations.

Cambridge Healthtech Institute's Fourth Annual
Smarter Lead Optimization
Changing the Paradigm

The large number of leads emerging from genomics and combinatorial chemistry demands that a new paradigm of lead optimization must be found. This new paradigm demands that companies move to parallel processes that evaluate binding affinity, ADME, drug properties, etc. earlier in the process in order to cut the time and costs lost in failed leads. It also brings new challenges and complications to the field. With the emergence of new technologies to help better identify the most promising leads a critical issue remains the validation and acceptance of these methods by regulatory agencies, as well as having the ability to run in parallel with other techniques in order to accelerate lead selection decisions. This meeting covers the crucial issues, implications, and strategies that allow you to employ new ways of reaching these goals faster, better and more economically. In addition, delegates will learn new techniques to improve existing leads to make them viable choices to continue through the drug development pipeline. Researchers working on technical developments driving this field, as well as those utilizing these new applications to overcome problems are encouraged to submit a title and summary describing their work for consideration as an oral or poster presentation by the scientific advisory committee.

Organized by:

Cambridge Healthtech Institute

Invited Speakers:

If you would like to submit a proposal to give a presentation at this meeting please send us, by email, a title and brief 3-5 sentence summary of a proposed topic on your recent work in the area of the chemoinformatics. All proposals are subject to review by the Scientific Advisory Committee to ensure the overall quality of the conference program.

For more information, please contact Edel O'Regan at: eoregan@healthtech.com

Deadline for Abstracts:

March 29, 2002

Registration:

http://www.healthtech.com/spring.asp

E-mail:

fvargus@healthtech.com

Posted by:

Frederick Vargus

Host:

wks253.healthtech.com